Votrient (pazopanib tablets) — Cigna
Thyroid Carcinoma, Medullary
Preferred products
- Caprelsa (vandetanib tablets)
- Cometriq (cabozantinib capsules)
- Retevmo (selpercatinib capsules)
- Gavreto (pralsetinib capsules)
Initial criteria
- Patient age ≥ 18 years
- Patient has tried at least one systemic therapy (e.g., Caprelsa, Cometriq, Retevmo, Gavreto)
Approval duration
1 year